A Placebo Controlled Trial of the Dopamine D-2 Receptor Agonist Ropinirole in Treatment of 60 Patients With Refractory Bipolar Depression.

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

We hypothesize that depressed patients who have not responded to their current antidepressant medication will respond to the addition of ropinirole to their current regimen at a rate better than placebo.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sheba Medical Center
• Collaborator: Jerusalem Mental Health Center
• Treatments: Dopamine; Dopamine Agents; Ropinirole

Criteria

Inclusion Criteria:

• DSM-IV Major Depression OR Bipolar I or II Disorder - Currently Depressed

• One month of a stable, adequate dose of antidepressant medication

• Bipolar patients must have a mood stabilizer

• At least 18 years old

• Modified HDRS-21 more than 16 (Scores reverse vegetative symptoms.)

• Informed Consent

Exclusion Criteria:

• CVA

• Antipsychotic Medication

• Drug or Alcohol Abuse

• Active Suicidality

• Rapid Cycling Bipolar Disorder

• Neurologic or Dementing Illness

• Psychosis

• Parkinsonism

• Pregnancy